Skip to main content
House committee recommends stronger oversight of 340B drug program

A House Energy and Commerce Committee report suggests that Congress clarify the intent of the 340B drug discount program, promote transparency and grant the Health Resources and Services Administration sufficient regulatory administration and oversight authority, among other recommendations.

Full Story: